Document is current
Any future updates will be listed below
-
Authors
Li, Yuping Derek https://orcid.org/0009-0006-5127-9023
Giles, David A.
Huang, Yi https://orcid.org/0000-0002-8379-9684
Kesarwani, Ashwani
Hu, Tong
Page, Logan
de Andrade Costa, Amanda
Luo, Jingqin https://orcid.org/0000-0003-2759-3072
Wolfarth, Alexandra
Choi, Donghoon
Dang, Mai T.
Kim, Albert H. https://orcid.org/0000-0002-1751-8493
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
Curiel, David T. https://orcid.org/0000-0003-3802-6014
Diamond, Michael S. https://orcid.org/0000-0002-8791-3165
Chheda, Milan G. https://orcid.org/0000-0001-8282-9098
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS107833)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS117149)
- License Information
-
More Information
Article History
Received: 18 November 2025
Accepted: 5 February 2026
First Online: 17 February 2026
Competing interests
: A.W. and D.C. are currently employed by NeoImmuneTech, Inc. J.F.D. is a consultant or on a Scientific Advisory Board for Rivervest, Bioline, Bluebird, Vertex, Incyte, NeoImmuneTech, and Macrogenics. J.F.D. has ownership investment in Magenta and WUGEN. M.S.D. is a consultant or on a Scientific Advisory Board for Inbios, IntegerBio, Akagera Medcines, GlaxoSmithKline, Merck, and Moderna. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, Bavarian Nordic, and Moderna. M.G.C. receives royalties from UpToDate, and has received research funding from Merck, Orbus Therapeutics, Incyte, and NeoimmuneTech. M.G.C. and M.S.D hold a patents on the use of oncolytic Zika virus to treat brain tumors (US12274725B2, EP3638304, EP3638304A4, JP7525853B2, AU2018283957A1). The remaining authors declare no competing interests.
